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ABSTRACT
The Na+/Mg2+ exchanger SLC41A1 (A1), a key component of intracellular Mg 
homeostasis (IMH), is the major cellular Mg2+ efflux system, and its overexpression 
decreases [Mg2+]intracellular. IMH plays an important role in the regulation of many 
cellular processes, including cellular signaling. However, whether the overexpression 
of A1 and the consequent drop of [Mg2+]i impact on intracellular signaling is unknown.
To examine the latter, we utilized dynamic mass redistribution (DMR) assay, 
PathScan® RTK signaling antibody (PRSA) array, confirmatory Western blot (WB) 
analyses of phosphorylation of kinases selected by PRSA, and mag-fura 2-assisted 
fast filter spectrometry (FFS).
We demonstrate here that the overexpression of A1 quantitatively and 
qualitatively changes the DMR signal evoked by the application of PAR-1-selective 
activating peptide and/or by changing [Mg2+]extracellular in HEK293 cells. PRSA profiling 
of the phosphorylation of important signaling nodes followed by confirmatory WB 
has revealed that, in HEK293 cells, A1 overexpression significantly attenuates the 
phosphorylation of Akt/PKB on Thr308 and/or Ser473 and of Erk1/2 on Thr202/Tyr204 in 
the presence of 0 or 1 mM (physiological) Mg2+ in the bath solution. The latter is also 
true for SH-SY5Y and HeLa cells. Overexpression of A1 in HEK293 cells significantly 
lowers [Mg2+]i in the presence of [Mg2+]e = 0 or 1 mM. This correlates with the 
observed attenuation of prosurvival Akt/PKB – Erk1/2 signaling in these cells.
Thus, A1 expression status and [Mg2+]e (and consequently also [Mg2+]i) modulate 
the complex physiological fingerprint of the cell and influence the activity of kinases 
involved in anti-apoptotic and, hence, pro-survival events in cells.
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INTRODUCTION
Magnesium (Mg2+) has been implicated in numerous 
vital cellular processes [1, 2, 3]. Its deficiency can have 
detrimental effects on the life of the cell [1]. Intracellular 
Mg2+ deficiency (IMD) can be caused: (1) by an 
insufficient supply of the ion from the extracellular milieu; 
(2) by mutation, i.e., non-functional or faulty cellular 
Mg2+ transport systems; or (3) by disrupted mechanisms 
regulating the influx, deposition, reposition, and efflux 
of the ion from the cell [1]. Little is known about the 
regulation of intracellular magnesium homeostasis 
(IMH), largely because of the lack of knowledge about 
the identities of cellular Mg2+ transport mechanisms, most 
of which have been discovered only recently.
Solute carrier SLC41A1 (further referred to 
as A1) has been characterized as being a Na+/Mg2+ 
exchanger (NME) and the major cellular Mg2+ efflux 
system ubiquitously expressed in various cell types [4–7 
and http://www.proteinatlas.org/ENSG00000133065-
SLC41A1/tissue]. The increased activity of NME is 
associated with many maladies, e.g., hypertension, 
preeclampsia, neurodegenerative disorders, cystic 
fibrosis, and diabetes mellitus [6, 8–13]. Even though 
IMD is assumed to contribute to the clinical image of the 
aforementioned maladies, whether it is also one of the 
primary causes of these diseases remains uncertain.
The function of A1 is regulated by cAMP-dependent 
protein kinase A (PKA) [5–7]. The increased PKA-
dependent phosphorylation of SLC41A1 leads to an 
increase of Mg2+ efflux capacity in transgenic HEK293 
cells [5, 6]. Levels of intracellular cAMP are controlled 
by various hormonal stimuli [13]. In several reports, the 
authors have demonstrated either the inhibitory (e.g., 
insulin; INS) or stimulatory (e.g., angiotensin II; ANG) 
effects of hormones on NME performance [13–15]. 
In particular, the inhibitory effect of INS may play a 
protective role against the excessive loss of Mg2+ from 
cells. The INS signaling axis IRTK – PI3K – Akt/PKB 
with the end effector phosphodiesterase 3b (PDE3b) 
is assumed to regulate (decrease) the level of cAMP 
and consequently also of PKA-dependent SLC41A1 
activation [13]. Many other extracellular signals might 
influence the activity of the PI3K-Akt/PKB signaling 
node. Among these are neuritin signaling via IRTK – 
PI3K – Akt/PKB; platelet-derived growth factor (PDGF) 
signaling via PDGFR – PI3K – Akt/PKB; epidermal 
growth factor (EGF) signaling via EGFR – PI3K – Akt/
PKB; insulin-like growth factor 1 (IGF-1) signaling via 
IGF-1R – PI3K – Akt/PKB; leptin (L) signaling via the 
LR – JAK2 – IRS2 signaling switch; growth hormone 
(GH), interferon-gamma (INFγ), and leukemia inhibitory 
factor (LIF) signaling via the GHR/INFγR/LIFR – JAK2 
– IRS1 signaling switch; and extracellular polyvalent-
ligand-activating integrin-linked FAK/c-Src dual kinase - 
PI3K - Akt/PKB signaling (Figure 1) [16–23]. Therefore, 
a reasonable assumption is that the activity of SLC41A1 
in various tissues is regulated by the interplay of various 
extracellular signals translated into the activity of the 
PI3K-Akt/PKB signaling node.
In our previous work, we have demonstrated 
that increased Mg2+ efflux capacity is achieved by 
the overexpression of A1 in HEK293 cells [4, 5]. The 
overexpression of A1 is also disease-related. Recently, this 
has been correlated with preeclampsia, a life-threatening 
condition in pregnant women [10]. Promotor and/or 
other regulatory sequences of A1 are assumed to possess 
androgen-responsive elements (AREs) that bind androgen 
receptor (AR) dimers [24, 25]. AR dimers then bind other 
transcription factors and regulate the transcription activity 
of the gene [11]. Apart from this, nothing is known about 
the regulation of A1 expression or about any impacts of 
A1 expression on the complex physiology of the cell.
Here, we have examined the effects of the A1 
expression status on dynamic mass redistribution (DMR) 
signals reflecting an integrated physiological response 
of the cell to (1) SFLLR-NH2 stimulation and (2) the 
modulation of [Mg2+]e. Furthermore, we have examined 
the impact of A1 overexpression and of [Mg2+]e on the 
phosphorylation of receptor tyrosine kinases (RTK) and 
important cellular signaling nodes.
RESULTS
Overexpression of A1 modulates the DMR 
profile of HEK293 cells
The DMR signal is an integrated response that 
consists of contributions from many cellular events 
induced by the ligand, thus providing alternative means 
for studying cell systems biology [26]. To date, DMR 
signals have been prevalently studied with regard to three 
classes of receptors: EGFR, Gq-coupled receptors, and Gs-
coupled receptors [26]. Here, we have tested the effect of 
SFLLR-NH2 in uninduced cells (further referred to as –
tet cells) and tet-induced cells overexpressing A1 (further 
referred to as +tet cells). SFLLR-NH2 is an agonist of 
G-protein-coupled protease-activated receptor 1 (PAR-1) 
and, at higher concentrations, also of PAR-2, which is used 
as a positive DMR control in HEK293 cells (PerkinElmer) 
[27–29].
As shown in Figure 2A, the addition of SFLLR-NH2 
(5 μM) to Ca2+- and Mg2+-free Hank’s balanced saline 
supplemented with 10 mM HEPES pH 7.4 (CMF-HBSS+; 
bath solution) induced a biphasic DMR signal in the –tet 
cells. The positive (increasing) DMR (P-DMR) signal 
was followed by a sequential negative (decay) signal 
(N-DMR). The peak amplitude of the DMR signal in the –
tet cells reached 141 ± 13.7 pm (N = 15). The DMR signal 
amplitude at the end of the measurement (36 min after 
the application of SFLLR-NH2) reached 103 ± 16.7 pm 
(N = 15). In the +tet cells, the application of SFLLR-NH2 
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induced an N-DMR signal followed by a weak P-DMR 
sequence (Figure 2A). The peak amplitude of the DMR 
signal in the +tet cells reached -83.3 ± 17.5 pm, and the 
amplitude at the end of the measurement was -70.8 ± 24.8 
pm (N = 15). Both the peak amplitude and the amplitude 
of the DMR signal at the end of the measurement in the 
+tet cells were significantly (both P < 0.001) different 
from those in the –tet cells.
To our knowledge, DMR technology has not 
previously been used to monitor the effect of [Mg2+]e 
(or other extracellular ions) on the integrated cellular 
response. Moreover, increased [Mg2+]e and natural 
polyamines (spermine and spermidine) have been shown 
to activate IR without the presence of INS [30].
Therefore, we next tested whether the changing of 
[Mg2+]e influenced the DMR profile of the –tet and +tet 
cells. During the measurements, the cells were bathed in 
CMF-HBSS+ plus Mg2+. The addition of Mg2+ (1, 3 or 10 
mM) induced dose-dependent DMR signals in both the 
–tet and +tet cells. However, the amplitude and overall 
profile of the DMR signals acquired in the –tet cells were 
markedly different from those in the +tet cells. Whereas 
the DMR signals in the –tet cells were clearly positive 
(P-DMR) at all three [Mg2+]e, the DMR signals in the 
+tet cells started as P-DMR signals and quickly reverted 
to decaying N-DMR signal sequences at all three [Mg2+]e 
(Figure 2B, Table 1).
We subsequently tested whether INS (400 μU/
mL) quantitatively and/or qualitatively changed the 
DMR signals seen in the –tet and +tet cells upon the 
addition of 1, 3, or 10 mM Mg2+ to the bath solution. As 
demonstrated in Figure 2C and Table 1, the simultaneous 
application of INS and Mg2+ had no pronounced effect on 
the quantitative and/or qualitative features of the [Mg2+]e-
dependent DMR signals in the –tet cells. However, in 
the +tet cells, the simultaneous application of INS and 3 
mM Mg2+ led to a significant (P < 0.05) increase of the 
peak amplitude of the P-DMR signal (Figure 2C, Table 
1). The application of INS together with 1 or 3 mM Mg2+ 
led to a significant (P < 0.001 and P < 0.05, respectively) 
Figure 1: Receptor-ligand network activating PI3K – Akt/PKB signaling node. Abbreviations: Akt/PKB, protein kinase B; 
cAMP, cyclic adenosine monophosphate; c-Src, proto-oncogene tyrosine-protein kinase; EGF, epidermal growth factor; EPL, extracellular 
polyvalent ligands; FAK, focal adhesion kinase; GH, growth hormone; INS, insulin; IRS1/2, insulin receptor substrate 1 and 2; I, 
integrin; PDGF, platelet-derived growth factor; IGF-1, insulin-like growth factor 1; JAK2, Janus kinase 2; L, leptin; N, neuritin; PDE3b, 
phosphodiesterase 3b; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PKA, protein kinase A; PKC λ/ζ, protein kinase C λ or ζ; R, 
receptor. Dashed black arrow indicates a speculative link between PKC and Na+/Mg2+ exchanger [65, 66]. Dashed red line indicates the 
inhibitory effect of SLC41A1 on Akt/PKB activity.
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reduction of the amplitude of the N-DMR signal at the end 
of the measurement (time point 36 min; Figure 2C, Table 
1). The simultaneous application of INS and 10 mM Mg2+ 
had no significant effect on the amplitude of the [Mg2+]e-
dependent DMR signal at the time point 36 min in +tet 
cells (Figure 2C, Table 1).
All DMR measurements were accompanied by 
a cell confluence assessment by using in-well imaging 
before the application of the particular effector, 
immediately after measurements and at 1.5 hours after 
the end of measurements (Supplementary Figure 1). 
Figure 3 demonstrates that none of the interventions and 
measurements had any significant effect on cell confluence 
and viability.
Taken together, our data reveal that the 
overexpression of A1 changes conspicuously the SFLLR-
NH2- or [Mg
2+]e-specific DMR fingerprint of HEK293 
cells, indicating a complex physiological difference 
between the –tet and +tet cells. Furthermore, INS has an 
effect on the [Mg2+]e-dependent DMR signal in the +tet 
cells at [Mg2+]e of 1 and 3 mM.
Overexpression of A1 and variation of [Mg2+]e 
modulate Akt/PKB signaling
As we had observed that both A1 overexpression 
and [Mg2+]e induce and/or modify the DMR signal, we 
next examined whether the overexpression of A1 and/or 
variation of [Mg2+]e influenced any of the 11 important 
signaling nodes included in the PathScan® RTK Signaling 
Antibody Array (PRSA). As shown in Figures 4 and 5A, 
prominent signals corresponding to phosphorylated Akt/
PKB-Thr308, Akt/PKB-Ser473, S6RP-Ser235/236, Erk1/2-
Thr202/Tyr204, and Src-Tyrpan were detected in the –tet and 
+tet cells, indicating that these kinases and their adjacent 
signaling cascades play an important role in the basal 
Figure 2: Real-time DMR signals measured in –tet and +tet HEK293 cells and induced by application of (A) SFLLR-NH2 (5 μM) or 
(B) Mg2+ at various concentrations (1, 3, or 10 mM). (C) Real-time DMR signals measured in –tet and +tet HEK293 cells and induced 
by application of Mg2+ at various concentrations (1, 3, or 10 mM) in the presence of INS (400 μU/mL) in the examined (CDF-HBSS+) 
solution. Black arrow indicates the application of SFLLR-NH2, of Mg
2+, or of Mg2+ with INS (Time 0 s). Before application of the respective 
effectors, –tet and +tet cells were equilibrated in CMF-HBSS+ for 90 min (60 min equilibration plus 30 min baseline measurements). 
DMR signals are given as the response in picometers (pm). Data were acquired at 90 s intervals. Data are presented as means (N = 15 for 
each tested condition) ± SE. Abbreviations: DMR, dynamic mass redistribution; INS, insulin; SFLLR-NH2, protease-activated receptor 1 
activating peptide; tet, tetracycline.
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Table 1: DMR signals presented as response in picometers (pm) and measured in –tet and +tet HEK293 cells at the 
maximum of P-DMR amplitude and at the time point of 36 min after application of the indicated [Mg2+]e, in the 
absence or presence of INS in the saline
INS (μU/mL) 0 400 0 400
Tet (1 μg/mL/15 hrs) - - + +
[Mg2+]e (mM) DMR (pm)
1 P-DMRmax 57.7 ± 4.38 59.8 ± 4.77 9.58 ± 4.72 19.9 ± 7.80
3 P-DMRmax 104 ± 8.91 92.5 ± 7.97 25.9 ± 6.41 44.3 ± 7.94
*
10 P-DMRmax 256 ± 22.2 314 ± 26.7 109 ± 20.3 96.8 ± 26.8
1 36 min 57.7 ± 4.38 59.8 ± 4.77 -63.5 ± 5.85 -11.8 ± 10.2***
3 36 min 104 ± 8.91 92.5 ± 7.97 -52.8 ± 8.13 -23.4 ± 10.3*
10 36 min 256 ± 22.2 314 ± 26.7 -47.7 ± 6.77 -40.1 ± 15.3
N = 15 for each tested condition. Significance of pairwise comparison INS 0 μU/mL vs. INS 400 μU/mL in both –tet and 
+tet cells at all tested [Mg2+]e: P
* < 0.05, P*** < 0.001. Abbreviations: DMR, dynamic mass redistribution; INS, insulin; 
P-DMRmax, maximal amplitude of positive DMR; tet, tetracycline.
Figure 3: Cell confluence assessed by using in-well imaging before the application of the particular effector(s), 
immediately after measurements, and 1. 5 hour after the end of measurements. Measurements were performed with –tet (A, 
C, E) and with +tet HEK293 cells (B, D, E) without INS (A, B) or with INS (400 μU/mL; C, D) in CMF-HBSS+. [Mg2+]e are indicated. 
Data are presented as means (for A – D, N = 12 – 15; for E, N = 9) ± SE. Abbreviations: 1.5 AM, 1.5 hrs after measurement; AM, after 
measurement; BM, before measurement; INS, insulin; SFLLR-NH2, protease-activated receptor 1 activating peptide; tet, tetracycline.
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processes in these cells. Furthermore, the overexpression 
of A1 (15 hrs, condition 0 (C0)) significantly attenuated 
(by 49.1± 9%; P < 0.001) the phosphorylation of Akt/
PKB-Ser473 in +tet cells when compared with –tet cells 
(Figures 4 and 5A). Moreover, the phosphorylation of 
Erk1/2-Thr202/Tyr204 was significantly attenuated (by 56.8 
± 7%; P < 0.05) in +tet cells when compared with –tet 
cells (Figures 4 and 5A). No statistical differences were 
detected between the levels of phosphorylation of Akt/
PKB-Thr308, S6RP-Ser235/236, and Src-Tyrpan in –tet and +tet 
cells (Figure 5A).
We also examined whether the variation of [Mg2+]e 
differently influenced the phosphorylation of Akt/PKB-
Thr308, Akt/PKB-Ser473, S6RP-Ser235/236, Erk1/2-Thr202/
Tyr204, Src-Tyrpan, or any of the other important signaling 
nodes included in PRSA in –tet and +tet cells (Figure 
5). First, we incubated –tet and +tet cells in Mg2+-free 
salt solution (CMF-HBSS+) for 20 min. This treatment 
(condition 1 (C1)) led to a significant (P < 0.001 and P < 
0.05, respectively) reduction (by 61 ± 8% and 47 ± 9%, 
respectively) of Akt/PKB-Ser473 and Erk1/2-Thr202/Tyr204 
phosphorylation in +tet cells when compared with –tet 
cells (Figure 5B). No significant differences in the levels 
of phosphorylation of Akt/PKB-Thr308, S6RP-Ser235/236, 
and Src-Tyrpan were detected between –tet and +tet cells 
(Figure 5B). Next, after C1, we provided –tet and +tet 
cells with HBSS+ supplemented with 10 mM Mg2+ for 30 
min (condition 2 (C2)). This led to a significantly higher 
(by 186 ± 56%; P < 0.05) phosphorylation of S6RP-
Ser235/236 in the +tet cells than in the –tet cells (Figure 5C). 
The levels of phosphorylation of Akt/PKB-Thr308, Akt/
PKB-Ser473, Erk1/2-Thr202/Tyr204, and Src-Tyrpan were not 
significantly different between –tet and +tet cells after C2 
(Figure 5C). As we had demonstrated that INS influenced 
the performance of A1 via classic INS signaling involving 
IRTK – PI3K – Akt/PKB [11], we provided –tet and 
+tet cells (after C1 + C2) with CMF-HBSS+ containing 
INS (400 μU/mL) for 25 min (condition 3 (C3)). This 
treatment led to comparable levels of phosphorylation of 
all detectable phospho-targets in +tet and –tet cells (Figure 
5D).
These data clearly indicate that A1 overexpression 
influences the phosphorylation (and, thus, the activity) 
of Akt/PKB-Ser473 and Erk1/2-Thr202/Tyr204 in Mg2+-free 
Figure 4: PathScan® RTK Signaling Antibody Arrays (PRSA) displaying phosphorylation of respective phospho-
substrates in –tet (control) and +tet (SLC41A1-overexpressing) HEK293 cells treated with C0, C1, C2, or C3. Two 
examples out of six independent experimental series are shown. Abbreviations: Akt/PKB, protein kinase B; C, condition; Src, proto-
oncogene tyrosine-protein kinase Src; Dur., duration; Erk1/2, extracellular signal-regulated kinase 1/2; INS, insulin; IRS-1, insulin receptor 
substrate 1; PC, positive control; S6RP, S6 ribosomal protein; tet, tetracycline.
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medium and in medium containing the physiological 
[Mg2+] (1 mM). Furthermore, they show that the presence 
of high 10 mM [Mg2+]e enhances the phosphorylation 
of S6RP-Ser235/236 in the +tet cells. Application of INS 
(400 μU/mL; 25 min) erases any differences in the 
phosphorylation status of Akt/PKB-Ser473 and Erk1/2-
Thr202/Tyr204 resulting from the different expression 
niveaus of A1 in –tet and +tet cells, as seen in Mg2+-free 
medium and medium supplied with 1 mM Mg2+.
The sequential experimental design allowed the 
pairwise comparisons of the effects of particular treatments 
(C0, C1, C2, C3) on the phosphorylation of the respective 
kinases in –tet and +tet cells. None of the treatments had 
a significant effect on the levels of phosphorylation of 
Akt/PKB-Thr308 in –tet cells (Figure 6A). A significant 
(P < 0.05) increase of Akt/PKB-Thr308 phosphorylation 
was evoked by C3 when compared with C0 and C1, but 
not with C2, in +tet cells (Figure 6A). A significantly (P 
Figure 5: Pairwise comparison of averaged relative densities of particular phospho-signals (Akt/PKB-Thr308, Akt/PKB-Ser473, S6RP-
Ser235/236, Erk1/2-Thr202/Tyr204, Src-Tyrpan) in –tet (control) and +tet (SLC41A1-overexpressing) HEK293 cells treated with (A) C0, (B) 
C1, (C) C2, or (D) C3, as obtained with PathScan® RTK Signaling Antibody Array (see Figure 4 for details). Each averaged density value 
results from six independent biological experiments (N/n = 6/12; respective phospho-signals were detected on chips in duplicate). Data 
are presented as means ± SE; *P < 0.05, ***P < 0.001. Abbreviations: Akt/PKB, protein kinase B; C, condition; Erk1/2, extracellular signal-
regulated kinase 1/2; RD, relative density; S6RP, S6 ribosomal protein; Src, proto-oncogene tyrosine-protein kinase Src; tet, tetracycline.
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< 0.05) lower level of Akt/PKB-Ser473 phosphorylation 
was detected in –tet cells after C2 when compared with 
that after C0 (Figure 6B). In +tet cells, a significantly (P < 
0.001) higher niveau of Akt/PKB-Ser473 phosphorylation 
was detected after C3 when compared with C0, C1, and 
C2 (Figure 6B). No significant changes of S6RP-Ser235/236 
phosphorylation were detected upon any of the applied 
treatments in the –tet cells (Figure 6C). Treatment C2 led 
to a significantly (P < 0.001) increased phosphorylation 
of S6RP-Ser235/236 when compared with treatments C0, C1, 
and C3 in +tet cells (Figure 6C). Moreover, no significant 
changes of Erk1/2-Thr202/Tyr204 phosphorylation were 
detected following any of the applied treatments in –tet 
cells (Figure 6D). Erk1/2-Thr202/Tyr204 phosphorylation was 
significantly (P < 0.05) reduced after C1 when compared 
with that after C2 or C3 in +tet cells (Figure 6D). None of 
the treatments induced a significant change of Src-Tyrpan 
phosphorylation in –tet or +tet cells (Figure 6E).
Taken together, the above data indicate that 
the modulation of [Mg2+]e and/or exposure to a high 
concentration of INS significantly affect the levels of Akt/
PKB-Thr308 phosphorylation in +tet cells, of the Akt/PKB-
Ser473 phosphorylation in both –tet and +tet cells, of the 
S6RP-Ser235/236 phosphorylation in +tet cells, and of the 
Erk1/2-Thr202/Tyr204 phosphorylation in +tet cells.
As we observed the most prominent effects of 
A1 overexpression and/or modulation of [Mg2+]e on the 
phosphorylation of Akt/PKB and Erk1/2, we decided to 
verify the PRSA results with Western blot (WB) analysis 
and densitometry.
Whereas PRSA had suggested only a numerical 
reduction in Akt/PKB-Thr308 phosphorylation by A1 
overexpression, the WB analysis revealed that Akt/PKB-
Thr308 was significantly (P < 0.01) less phosphorylated 
in cells overexpressing A1 and grown in the presence 
of [Mg2+]e at 1 mM (C0) when compared with –tet cells 
under the same conditions (Figures 7 and 8A). Coherent 
with the results obtained with PRSA, the WB data show 
that the phosphorylation of Akt/PKB-Ser473 is indeed 
significantly (P < 0.05 and P < 0.01) attenuated in +tet 
cells when compared with that in –tet cells, under both C0 
and C1 (Figures 7 and 8B).
Figure 6: Between-treatments (C0, C1, C2, C3; see Figure 4 for details) comparison of averaged relative densities of (A) Akt/PKB-Thr308 
phospho-signals, (B) Akt/PKB-Ser473 phospho-signals, (C) S6RP-Ser235/236 phospho-signals, (D) Erk1/2-Thr202/Tyr204 phospho-signals, and 
(E) Src-Tyrpan phospho-signals in –tet (control) and +tet (SLC41A1-overexpressing) HEK293 cells, as obtained with PathScan® RTK 
Signaling Antibody Array (PRSA). Each averaged density value results from six independent biological experiments (N/n = 6/12 (respective 
phospho-signals were detected on chips in duplicate)). Data are presented as means ± SE; a vs. b P < 0.05. Abbreviations: Akt/PKB, protein 
kinase B; C, condition; Erk1/2, extracellular signal-regulated kinase 1/2; RD, relative density; S6RP, S6 ribosomal protein; Src, proto-
oncogene tyrosine-protein kinase Src; tet, tetracycline.
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The comparisons of Akt/PKB-Thr308 phosphorylation 
between treatments revealed the significantly (P < 0.05) 
higher level of Thr308 phosphorylation in –tet cells after 
C3 when compared with C1 and C2 (Figure 8A). This 
was also the case in +tet cells (Figure 8A). In the case 
of Akt/PKB-Ser473, the comparison of its phosphorylation 
between treatments showed a significantly (P < 0.05) 
increased niveau of phospho-Ser473 in –tet cells after C3 
when compared with C1 and C2 (Figure 8B). In +tet 
cells after C3, the level of Ser473 phosphorylation was 
significantly (P < 0.05) higher than that after C1 (Figure 
8B).
The WB analysis confirmed the PRSA results 
showing that Erk1/2-Thr202/Tyr204 phosphorylation was 
significantly (P < 0.05) reduced in cells overexpressing 
A1 and grown in the presence of [Mg2+]e at 1 mM 
(C0) when compared with –tet cells under the same 
conditions (Figures 9 and 10). Although the PRSA data 
showed a significant reduction of Erk1/2-Thr202/Tyr204 
phosphorylation in +tet cells under C1 (compared with 
–tet cells under C1), the reduction of Erk1/2-Thr202/
Tyr204 phosphorylation in +tet cells under C1 as detected 
with WB analysis was not significant (P = 0.17) when 
compared with –tet cells under C1.
The comparisons of the Erk1/2-Thr202/Tyr204 
phosphorylation between treatments revealed the 
significantly (P < 0.05) higher level of Thr202/Tyr204 
phosphorylation in +tet cells after C2 when compared with 
C0 and C1 (Figure 10). However, this was not the case in 
–tet cells (Figure 10).
In summary, the densitometric WB and PRSA data 
demonstrated similar changes in the phosphorylation 
profile (and thus activity) of Akt/PKB and Erk1/2 in 
response to the expression status of A1.
Next, we examined whether the above-described 
attenuation of the phosphorylation of Akt/PKB triggered 
by A1 overexpression is a common phenomenon in various 
cell types, or whether it is limited to HEK293 cells only. 
SH-SY5Y neuroblastoma-derived cells were transfected 
with empty vector (SH-SY5Y-A- cells) or vector carrying 
and constitutively expressing A1 (SH-SY5Y-A+ cells).
Coherent with data acquired from HEK293 cells, 
the WB analysis revealed that Akt/PKB-Thr308 was 
significantly (P < 0.01) less phosphorylated in SH-
SY5Y-A+ cells overexpressing A1 and grown in the 
presence of [Mg2+]e at 1 mM (C0) when compared 
with SH-SY5Y-A- cells under the same conditions 
(Supplementary Figures 2 and 3A). Moreover, the 
phosphorylation of Akt/PKB-Ser473 was significantly (P < 
0.01 and P < 0.05) attenuated in SH-SY5Y-A+ cells when 
compared with that in SH-SY5Y-A- cells, under both C0 
and C1 (Supplementary Figures 2 and 3B). No significant 
differences in phosphorylation of both Akt/PKB-Thr308 and 
Akt/PKB-Ser473 were detected between SH-SY5Y-A- and 
SH-SY5Y-A+ cells under either C2 or C3 (Supplementary 
Figures 2, 3A and 3B).
Between-treatments comparisons of Akt/PKB-Thr308 
phosphorylation revealed the significantly (P < 0.05) 
higher level of Thr308 phosphorylation in SH-SY5Y-A- 
cells after C3 when compared with C1 and C2 and under 
C0 when compared with C2 (Supplementary Figure 3A). 
In SH-SY5Y-A+ cells, the latter was observed, except that 
no significant difference was detected between C0 and 
C2 (Supplementary Figure 3A). A comparison of Akt/
PKB-Ser473 phosphorylation between treatments showed 
Figure 7: WB analysis of the phosphorylation status of Akt/PKB-Thr308 and Akt/PKB- Ser473 in response to the 
treatment conditions C0, C1, C2, or C3 (see Figure 4 for details) in –tet (control) and +tet (SLC41A1-overexpressing) 
HEK293 cells. One representative experiment of, in total, five independent biological experiments is shown. RPL19 was used as a 
loading reference and was detected subsequent to the phospho-signals on the same blots. Abbreviations: Akt/PKB, protein kinase B; C, 
condition; RPL19, 60S ribosomal protein L19; tet, tetracycline; WB, Western blot.
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Figure 8: Pairwise comparison of relative adjusted densities of Akt/PKB-Thr308 (A) and Akt/PKB-Ser473 (B) phospho-signals and between-
treatments (C0, C1, C2, C3; see Figure 4 for details) comparison of relative adjusted densities of Akt/PKB-Thr308 (A) and Akt/PKB-Ser473 
(B) phospho-signals in –tet (control) and +tet (SLC41A1-overexpressing) HEK293 cells, obtained with WB. Data are presented as means 
(N = 5) ± SE. Pairwise comparisons: Significance is indicated (*P < 0.05, **P < 0.01). Between-treatment comparisons: Labeled means 
without a common letter differ (P < 0.05). Small letters were used for the between-treatment comparisons in –tet group and capital letters 
in +tet group. Abbreviations: Akt/PKB, protein kinase B; C, condition; RAD, relative adjusted density; tet, tetracycline; WB, Western blot.
Figure 9: WB analysis of the phosphorylation status of Erk1/2-Thr202/Tyr204 in response to the treatment conditions 
C0, C1, C2, or C3 (see Figure 4 for details) in –tet (control) and +tet (SLC41A1-overexpressing) HEK293 cells. One 
representative experiment of, in total, five independent biological experiments is shown, in which total Erk1/2 and the phospho-signals 
of Erk1/2-Thr202/Tyr204 were detected in parallel. Abbreviations: C, condition; Erk1/2, extracellular signal-regulated kinase 1/2; tet, 
tetracycline; WB, Western blot.
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significantly (P < 0.05) increased levels of phosphorylated 
Ser473 in both SH-SY5Y-A- and SH-SY5Y-A+ cells after 
C3 when compared with C1 and C2, and in C0 when 
compared with C2 (Supplementary Figure 3B).
The Akt/PKB-Thr308 and -Ser473 phosphorylation 
profiles in HEK293 cells and in SH-SY5Y cells in 
response to the expression status of SLC41A1 and the 
status of the extracellular and intracellular Mg2+ largely 
overlaps. The levels of phosphorylation of both Thr308 and 
Ser473 are much higher under C3 in SH-SY5Y cells when 
compared with HEK293 cells suggesting (Figure 8A and 
8B vers. Supplementary Figure 3A and 3B) that SH-SY5Y 
cells are obviously better responders regarding the INS 
stimulation.
Consequently, we examined the phosphorylation 
status of Erk1/2-Thr202/Tyr204 in SH-SY5Y-A- and SH-
SY5Y-A+ cells. Similar to HEK293 cells, we detected a 
significant (P < 0.001) reduction of Erk1/2-Thr202/Tyr204 
phosphorylation related to the overexpression of A1 in SH-
SY5Y-A+ cells when compared with SH-SY5Y-A- under 
C0 (Supplementary Figures 4 and 5). A significantly (P < 
0.05) higher phosphorylation of Erk1/2-Thr202/Tyr204 was 
Figure 10: Pairwise comparison of relative adjusted densities of Erk1/2-Thr202/Tyr204 phospho-signals and between-
treatments (C0, C1, C2, C3; see Figure 4 for details) comparison of relative adjusted densities of Erk1/2-Thr202/
Tyr204 phospho-signals in –tet (control) and +tet (SLC41A1-overexpressing) HEK293 cells, obtained with WB. Data are 
presented as means (N = 5) ± SE. Pairwise comparisons: significance is indicated (*P < 0.05). Between-treatment comparisons: Labeled 
means without a common letter differ (P < 0.05). Small letters were used for the between-treatment comparisons in –tet group and capital 
letters in +tet group. Abbreviations: C, condition; Erk1/2, extracellular signal-regulated kinase 1/2; RAD, relative adjusted density; tet, 
tetracycline; WB, Western blot.
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detected in SH-SY5Y-A+ under C3 when compared with 
SH-SY5Y-A- cells treated in the same way (Supplementary 
Figure 5). This indicates that the overexpression of A1 
facilitates the effect of INS on Erk1/2 phosphorylation 
and, thus, its activity in SH-SY5Y cells.
Statistical analysis for the between-treatment 
comparisons were missing in Supplementary Figure 5 
and are now included in the new Supplementary Figure 5 
which is attached. However, the same comparison in SH-
SY5Y-A+ cells revealed significantly (P < 0.05) higher 
Erk1/2-Thr202/Tyr204 phosphorylation in cells treated 
under C3 compared with cells treated under C0 or C1 
(Supplementary Figure 5).
Finally, we examined the correlation between A1 
overexpression and the phosphorylation status of Akt/
PKB and ERK1/2 in HeLa adenocarcinoma-derived 
cells with tet inducible expression of A1. Under our 
experimental conditions, basal phosphorylation of Akt/
PKB at Ser473 and, in particular, at Thr308 was extremely 
low in this cell line. Low basal Akt/PKB phosphorylation 
in HeLa cells was also found by other authors by using 
the phospho-specific antibodies used in this study [31]. 
We therefore compared Akt/PKB phosphorylation 
between –tet and +tet cells in this cell line only under 
C3, as only INS treatment stimulated the sufficient 
detectable phosphorylation of both Thr308 and Ser473. 
As shown in Supplementary Figures 6 and 7, the INS-
induced phosphorylation of Thr308 was significantly (P < 
0.05) lower in +tet cells in comparison with in –tet cells. 
Moreover, phosphorylation of Ser473 was significantly (P 
< 0.01) lower in +tet cell than in –tet cells (Supplementary 
Figures 6 and 7).
The phosphorylation of Erk1/2-Thr202/Tyr204 
in HeLa cells was well detectable under all tested 
conditions. Erk1/2 was significantly (P < 0.05) less 
phosphorylated in +tet cells when compared with –tet 
cells (Supplementary Figures 8 and 9). The comparison 
of Erk1/2 phosphorylation between –tet and +tet cells 
under C1, C2, and C3 revealed no significant differences 
(Supplementary Figures 8 and 9).
In between-treatments comparisons of Erk1/2-
Thr202/Tyr204 phosphorylation in –tet cells, we found a 
significant (P < 0.05) difference between treatment C0 
and C1 (Supplementary Figure 9). The same comparison 
in +tet cells revealed no significant differences between 
particular conditions (Supplementary Figure 9).
In brief summary, WB analyses revealed that, in 
HEK293 and SH-SY5Y cells, the overexpression of A1 
correlated with the decrease of Akt/PKB and Erk1/2-
Thr202/Tyr204 at a physiological [Mg2+]e of 1 mM (C0). 
The Akt/PKB phosphorylation was below the detection 
limit of WB in HeLa cells under all tested [Mg2+]e (C0, 
C1, and C2). However, it became detectable upon use 
of hyperinsulinemic [INS]e of 400 μU/mL with no Mg
2+ 
being present in the bath solution, and overexpression of 
A1 under this condition lead to a significantly (P < 0.05, P 
< 0.01) lower Akt/PKB-Thr308 and -Ser473 phosphorylation 
when compared with Akt/PKB-Thr308 and -Ser473 
phosphorylation in –tet HeLa cells.
Overexpression of SLC41A1 clearly modifies 
[Mg2+]i at all tested conditions
In our previous work, we have demonstrated that 
SLC41A1 is a functional NME that operates primarily in 
efflux mode under normal physiological conditions [2, 3, 
4, 11]. However, A1 may operate also in reverse mode, 
thus conducting Mg2+ influx, but only if a sufficiently 
large [Mg2+]e is provided [5, 6, 13]. Here, we measured 
[Mg2+]i in –tet and +tet HEK293 cells after treatment C0, 
C1, C2, and C3. The results are summarized in Table 2. 
Overexpression of A1 (15 hrs) lead to a significant (P < 
0.001) reduction of [Mg2+]i when compared with [Mg
2+]i in 
control –tet cells (both –tet and +tet cells were measured 
at [Mg2+]e = 1 mM; C0). +Tet cells incubated 30 min in 
CMF-HBSS+ ([Mg2+]e = 0 mM; C1) had significantly 
(P < 0.001) lower [Mg2+]i when compared with [Mg
2+]i 
in control –tet cells treated in the same way. The [Mg2+]i 
determined in +tet cells treated under C2 (cells were 
bathed for 30 min in CMF-HBSS+ and 30 min in HBSS+ 
containing [Mg2+]e = 10 mM) were significantly (P < 
0.01) higher than the [Mg2+]i in –tet cells treated under 
C2. Finally, we measured [Mg2+]i in –tet and +tet cells that 
were bathed for 30 min in CMF-HBSS+ followed by a 30 
min bath in HBSS+ containing [Mg2+]e = 10 mM and a 25 
minutes bath in CMF-HBSS+ supplemented with 400 μU/
mL of INS (C3). As is evident from Table 2, the [Mg2+]i 
measurements in –tet cells were not significantly different 
from those measured in +tet cells.
From our previous, the expression levels 
of SLC41A1 significantly influence the status of 
[Mg2+]i under C0, C1, and C2. In contrast, under C3 
(hyperinsulinemic concentration of INS), the SLC41A1 
expression level did not significantly influence [Mg2+]i.
The multiple pairwise comparison of [Mg2+]i 
between particular conditions within the group of –tet 
cells (summarized in Table 3) revealed no significant 
difference between the [Mg2+]i of cells under C1 when 
compared with [Mg2+]i of cells treated under C0. However, 
[Mg2+]i of cells under C1 were significantly (P < 0.05) 
lower when compared with [Mg2+]i of cells under C2 or 
C3. The concentrations of intracellular Mg2+ measured in 
cells under C2 were not significantly different from Mg2+ 
concentrations determined in cells under C0 or C3; [Mg2+]i 
of cells under C0 were significantly (P < 0.05) lower when 
compared with [Mg2+]i of cells under C3.
The multiple pairwise comparison of [Mg2+]i 
between particular conditions within the group of +tet 
cells (summarized in Table 3) showed that [Mg2+]i of cells 
under C1 were significantly (P < 0.05) lower than [Mg2+]i 
of cells treated under C0, C2, or C3. [Mg2+]i of cells under 
C2 were significantly (P < 0.05) higher when compared 
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with [Mg2+]i of cells under C0 and C1, but not C3. [Mg
2+]i 
of cells under C3 were significantly (P < 0.05) higher than 
[Mg2+]i of cells under C1, but not C0 or C2.
DISCUSSION
The involvement of Mg2+ in more than 300 
distinctive enzymatic reactions and key cellular 
processes substantiates the need for the efficient cellular 
regulation of [Mg2+]i [1]. Regulated active Mg
2+ transport 
mechanisms are essential for the maintenance of IMH [7].
Extracellular signals (e.g., hormones) and 
intracellular signaling play an important role in the 
regulation of Mg2+ transporters and, thus, IMH [1]. 
However, the paucity of information concerning the 
molecular biology of the respective cellular Mg2+ transport 
systems makes our understanding of the role of cellular 
signaling in IMH incomplete.
NME A1 is a key component of IMH regulation 
and is still the only known ubiquitously expressed Mg2+ 
efflux system in cells [4–7, 10, 11, 13]. Recently, we have 
demonstrated that INS regulates the NME activity of A1 
via the “classic” signaling cascade IRTK – PI3K – Akt/
PKB [13]. Moreover, ANG has been implicated in the 
regulation of NME [32]. Both INS and ANG influence 
intracellular cAMP levels and, consequently, the PKA 
activity that triggers A1 activity [13, 33].
Overexpression of A1 results in a decrease of the 
basal [Mg2+]i in cells cultured at the physiological [Mg
2+]e 
of 1 mM (Tables 2 and 3) [4, 5]. Goytain and Quamme 
have demonstrated that a restriction of Mg2+ intake induces 
the upregulation of A1 expression in mice [34]. Nothing 
is known about the signaling involved in the regulation of 
A1 transcription, apart from the work of Romanuik and 
Hwang [24] who have identified A1 as being an androgen-
responsive gene and who have therefore assumed the 
existence of AREs in regulatory sequences surrounding 
Table 3: Pairwise comparisons of [Mg2+]i measured separately in –tet HEK293 cells or in +tet HEK293 cells under 
C0 through C3
tet -tet +tet















± 0.04 0.67 ± 0.04
Significance (defined by 
P < 0.05) bc c ab a B C A AB
Conditions were as previously described in legend for Table 2. Letter code indicates statistically significant differences 
between compared datasets. Abbreviations: C, condition; tet, tetracycline.




N [Mg2+]i (mM) N [Mg2+]i (mM)
C0 17 0.31 ± 0.08 15 0.23 ± 0.03 P < 0.001
C1 18 0.21 ± 0.07 18 0.05 ± 0.02 P < 0.001
C2 10 0.57 ± 0.06 10 0.77 ± 0.04 P < 0.01
C3 10 0.75 ± 0.07 10 0.67 ± 0.04 P = 0.39
Conditions: C0, [Mg2+]i was measured in –tet and +tet cells immediately after 30-min loading with mag-fura 2 fluorescent 
probe upon presence of [Mg2+]e = 1 mM; C1, [Mg
2+]i was measured in –tet and +tet cells after 30-min loading with mag-fura 
2 fluorescent probe in CMF-HBSS+; C2, [Mg2+]i was measured in –tet and +tet cells after 30-min loading with mag-fura 
2 fluorescent probe in CMF-HBSS+ followed by 30-min incubation of the cells in HBSS+ containing 10 mM Mg2+; C3, 
[Mg2+]i was measured in –tet and +tet cells after 30-min loading with mag-fura 2 fluorescent probe in Mg
2+-free HBSS+ 
followed by 30-min incubation of the cells in HBSS+ containing 10 mM Mg2+ and successively by 25-min incubation of 
the cells in CMF-HBSS+ provided with INS (400 μU/mL). Abbreviations: C, condition; CMF-HBSS+, Ca2+- and Mg2+-free 
Hank’s balanced salt solution plus 10 mM HEPES pH 7.4; tet, tetracycline.
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the coding regions of A1 [24, 25]. Furthermore, nothing is 
known about the impact of A1 overexpression on cellular 
signaling and complex cell physiology.
Our data (Figure 2) demonstrate that the 
overexpression of A1 completely changes the SFLLR-
NH2- and [Mg
2+]e-induced DMR fingerprint of HEK293 
cells, thus identifying the A1 expression level as being a 
bona fide discriminant able to modify complex cellular 
responses to external signals translated into a measurable 
DMR signal. Indeed, these data indicate that not only 
extracellular signals and adjacent afferent signaling 
influence A1 (or A1) at the transcriptional and the 
functional levels, but also vice versa, i.e., that levels of A1 
transcription influence intracellular signaling.
Akt/PKB has a central role in cellular signaling and 
in the regulation of proliferation, growth, and apoptosis 
[35, 36]. The phosphorylation of Thr308 activates Akt/
PKB, although the phosphorylation of Thr308 and 
Ser473 is required for its full activity. Significantly, the 
phosphorylation of Ser473 alone has little effect on Akt/
PKB activity [35, 36]. Several studies have implicated 
Mg2+ in the regulation of Akt/PKB activity [37, 38]. 
Krueger et al. have demonstrated that elevated [Mg2+]e (3.3 
mM) increases cell proliferation in neural cells in culture 
and have observed that increased Akt/PKB activation, 
comparable with activation by INS (200 nM), follows 
Mg2+ treatment [37]. The activity of Akt/PKB results 
from the orchestrated actions of kinase PDK-1, which 
phosphorylates Thr308; kinase complex mTOR/RICTOR/
GβL, which phosphorylates Ser473; kinase PI3K, which 
phosphorylates both Thr308 and Ser473 in Akt/PKB isoform 
1 or Ser474 alone in isoform 2; phosphatase PP2A, which 
dephosphorylates Thr308; and the PHLPP phosphatases, 
which dephosphorylate Ser473 [39–44]. PHLPP is a 
member of the protein phosphatase Mg2+-activated (PPM) 
subfamily of phosphatases. It requires Mg2+ for its catalytic 
activity [44]. Mg2+ also plays a role in the activation of 
PP2A, but only in complex with ATP [45]. Low [Mg2+]e is 
also assumed to activate PI3K [46].
Here, we have demonstrated that the overexpression 
of NME A1 significantly attenuates the phosphorylation of 
Akt/PKB at both Thr308 and Ser473 (Figures 5A, 5B, 8A, 8B, 
Supplementary Figure 3). These data nicely complement 
the aforementioned work of Krueger and colleagues [37]. 
However, the above also indicates that the low [Mg2+]i 
that results from the overexpression of A1 should down-
regulate PHLPP, and perhaps PP2A, and activate PI3K to 
increase the phosphorylation of both Thr308 and Ser473 or 
at least to keep their phosphorylation status at a sustained 
level (Supplementary Figure 10A). Hence, an as yet 
unknown regulatory mechanism must exist that is potent 
enough to increase the activity of PHLPP and PP2A and to 
decrease that of PI3K, PDK-1, and mTOR/RICTOR/GβL 
at the lower [Mg2+]i induced by the overexpression of A1 
(Supplementary Figure 10B). Whether such a regulator is 
the recently identified Mg2+ homeostatic factor CNNM2 
remains to be examined [47].
Further, our data indicate that the variation of 
extracellular Mg2+ (C1, C2) also contributes to the 
modulation of the Akt/PKB phosphorylation on Thr308 and 
Ser473 in both the cells with endogenous A1 expression and 
A1-overexpressing cells, although the expression status 
of A1 remains a superior discriminant compared with 
the status of [Mg2+]e. Our results also suggest that INS 
stimulates the phosphorylation of both Thr308 and Ser473 
independently of the presence of Mg2+ in the extracellular 
solution. The latter is also supported by the observation 
that, irrespective of A1 expression status, the presence 
of [Mg2+]e = 10 mM (C2) was insufficient to increase the 
phosphorylation of Akt/PKB (at both Thr308 and Ser473) 
beyond the WB detection threshold in HeLa cells, whereas 
the hyperinsulinemic concentration of INS induced a 
detectable massive phosphorylation of both Thr308 and 
Ser473 of Akt/PKB in these cells, even without presence 
of Mg2+ in external solution (Supplementary Figures 6 
and 7).
Notably, Erk1/2-Thr202/Tyr204 phosphorylation is 
significantly reduced in +tet HEK293 and in +tet HeLa 
and SH-SY5Y-A+ cells in the presence of physiological 
Mg2+ (1 mM) or with no Mg2+ (only in HEK293 cells) 
in the bath solution (Figures 5A, 5B, 10, Supplementary 
Figures 5 and 9). The phosphorylation of both Thr202 
and Tyr204 residues is required for its activity [48]. 
Therefore, we can conclude that the overexpression of 
A1 contributes to the reduction of Erk1/2 kinase activity 
and thus to the modulation of its signaling in processes 
such as proliferation and/or apoptotic events in cells [49, 
50]. The Ras – Erk1/2 and PI3K – Akt/PKB – mTORC1 
pathways regulate each other via cross-inhibition and 
cross-activation [51]. Our data indicate that the lack of 
[Mg2+]i, caused by the overexpression of A1 in the +tet 
cells bathed in medium containing no Mg2+ or 1 mM 
Mg2+ leads to an attenuation of both cascades (Tables 2 
and 3) [4, 5]. Indeed, one can speculate that oscillations 
of [Mg2+]i play a critical role in the regulation of both 
the aforementioned cascades and their crosstalk. Hence, 
from a larger perspective, A1 can be assumed to play 
a significant role in the regulation of Erk1/2 and Akt/
PKB signaling and their orchestration in basic cellular 
processes, such as proliferation and apoptosis.
Ser/Thr kinase mTOR is a key integrator of growth-
factor-activated and nutrient-sensing pathways in the cell. 
It is activated by Akt/PKB, which phosphorylates tuberin 
(TSC2) at multiple sites relieving the inhibitory effects 
of the hamartin-tuberin (TSC1-TSC2) complex on Rheb 
and mTOR complex 1 (mTORC1) [52–54]. Activated 
mTORC1 phosphorylates ribosomal S6 kinase (S6K1), 
which phosphorylates S6RP [54]. Thus, the increased 
phosphorylation of S6RP on Ser235/236, as seen only in 
A1-overexpressing cells at high [Mg2+]e, indicates the 
increased activity of mTOR (Figure 5C). In our previous 
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work, we have shown that the presence of high [Mg2+]e 
(10 mM) is potent enough to revert the mode of A1 
operation from Mg2+-extrusion to Mg2+-influx leading 
to a significant increase of [Mg2+]i in A1-overexpressing 
cells [4–6]. Therefore, both the increase of [Mg2+]i and 
the increased levels of A1 expression can be assumed to 
be necessary to stimulate mTOR signaling. In contrast, 
the overexpression of A1 paralleled with the presence 
of no Mg2+ or physiological [Mg2+] (1 mM) in the bath 
solution significantly attenuates the phosphorylation of 
Thr308 and Ser473 of Akt/PKB in the +tet cells (Figures 5A, 
5B, 8A, 8B, Supplementary Figure 3), and, hence, under 
this condition, the attenuated Akt/PKB activity leads 
to the increased stability of the TSC1-TSC2 complex 
and the silencing of mTOR signaling (when compared 
with [Mg2+](10 mM); Figure 5A, 5B, 5D) [52]. Rubin 
has proposed mTOR as a key player in his Membrane-
Magnesium-Mitosis (MMM) model, which holds that any 
rise in [Mg2+]i increases MgATP
2- and activates mTOR 
[55]. Whereas most of the kinases in the PI3K - Akt/PKB 
– mTOR signaling cascade have a low Km for MgATP
2-, 
mTOR has a high requirement that approximates the 
level of free Mg2+ in the cell [55]. Furthermore, the 
intracellular levels of free Mg2+ might play a crucial role 
in the regulation of the activities of the principal mTOR 
modulators such as Rheb and Rag GTPases [56–58]. Thus, 
A1 (its functional and expression status) as a prominent 
regulator of [Mg2+]i and of Akt/PKB activity is a factor of 
paramount importance in the MMM model.
Perturbed Akt/PKB signaling has been implicated 
in several serious ailments, e.g., peripheral INS resistance 
and diabetes, Alzheimer’s and Parkinson’s diseases (AD, 
PD), and cancer [59–61]. In particular, in cancer, the 
increased activity of Akt/PKB is considered as being 
a major factor defining the invasive abilities of tumors 
[61]. For example, the constitutive phosphorylation of 
Akt/PKB, particularly on Ser473, is associated with poor 
prognosis in acute myeloid leukemia [62]. Increased 
Akt/PKB expression and activity have been detected in 
aggressive human gastric cancers and in breast, prostate, 
ovarian, and brain tumors [63]. Thus, an understanding of 
the modalities influencing Akt/PKB activity is absolutely 
essential for the effective targeting and manipulation of 
Akt/PKB activity in the aforementioned diseases.
Hypomagnesemia and intracellular Mg2+ deficiency 
are the hallmarks of diseases such as diabetes, AD, or 
PD and are assumed negatively to influence the course 
of these diseases and therapeutic outcomes [1, 11]. In 
contrast, cancer cells are known to retain higher Mg2+ 
concentrations, in agreement with the pro-proliferative 
effect of Mg2+ [34, 64]. Although the identity of NME was 
unknown at the time, Wolf and Cittadini predicted as early 
as 1999 that, in tumor cells, the disturbed Mg2+ content is 
probably attributable to the inhibition of Mg efflux via the 
Na+/Mg2+ antiporter [64]. Mastrototaro et al. have recently 
demonstrated that the INS-activated IRTK – PI3K – Akt/
PKB signaling axis constitutes an important mechanism 
controlling the activity of NME A1 [13]. Our present work 
not only complements the work of Wolf and Cittadini 
and of Mastrototaro et al., but also most importantly 
demonstrates that the mutual control of the functions of 
Akt/PKB (and of Erk1/2 and mTOR) and A1 is delicately 
balanced, and that the deregulation of either one might 
result in disease.
Our results also provide support for the role of 
IMH and the genetics of its molecular constituents in 
the pathophysiology of prominent human ailments such 
as cancer. Various aberrant ion-transporting proteins 
(channels, pumps, and carriers) or the deranged expression 
of their normal (healthy) variants have been experimentally 
linked to the process of tumorigenesis (tumor development 
and progression) [67]. However, the involvement of 
NME in tumorigenesis has only been hypothesized [64]. 
Our data provide a solid piece of evidence that NME A1 
influences the Akt/PKB signaling node, which thus might 
interfere with molecular mechanisms discriminating 
between pro-apoptotic and pro-survival cellular events. 
In the future, the correlation of the transcriptional and 
functional parameters of NME A1 and Akt/PKB signaling 
in cancer and also the other disease conditions mentioned 
above will be of great interest.
We conclude that the expression status of A1 and 
the status of [Mg2+]e (and consequently also of [Mg
2+]i) 
play a role in the regulation of Akt/PKB and Erk1/2 
activities and the complex physiological response to 
extracellular stimuli. The levels of expression of A1 
might be considered as a molecular marker in disease 
conditions hallmarked by disrupted Akt/PKB signaling 
and/or disturbed IMH. Furthermore, the pharmacological 
management of the expression and function of A1 might 
find its place in the therapy of “Akt-opathies”.
MATERIALS AND METHODS
Cloning of SLC41A1 into pcDNA5/TO
The coding sequence of SLC41A1 with an 
N-terminal HA- (hemagglutinin) tag and a C-terminal 
strep-tag was produced by gene synthesis (ShineGene Bio-
Technologies, Inc.) and cloned into pcDNA5/TO via the 
restriction sites KpnI and XhoI.
Cell culture
HEK293(tet)↑(FLAG-SLC41A1); stable 
tetracycline-(tet)-inducible HEK293 cells overexpressing 
N-terminal FLAG-tagged Na+/Mg2+ exchanger A1. 
Cells were cultured as previously described by Kolisek 
and colleagues [4, 5]. Protein expression was induced 
by the addition of tetracycline (1 μg/mL) for 15 
hours. The detailed characteristics of A1 expression 
in HEK293(tet)↑(FLAG-SLC41A1) cells have been 
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published previously [4, 5]. No leakiness of the expression 
of recombinant SLC41A1 was detected in –tet cells 
(Supplementary Figure 11).
The T-REx™-HeLa cell line was purchased 
from Thermo Fisher Scientific and grown in DMEM 
(Biochrom) supplemented with 10% FBS and stable 
glutamine, 1% Pen-Strep, and 5 μg/ml blasticidin.
The human neuroblastoma cell line SH-SY5Y 
(ATCC CRL-2266) was cultured in Dulbecco's MEM/
Ham's F-12 (1:1) (Biochrom) supplemented with 10% 
FBS and stable glutamine and 1% Pen-Strep.
Transient transfection of SH-SY5Y and HeLa 
cells
SH-SY5Y and HeLa cells were transiently 
transfected with pcDNA5/TO-SLC41A1 or the respective 
empty control vector by using TurboFect transfection 
reagent (Thermo Fisher Scientific). For SH-SY5Y, three 
million cells were seeded per T-75 flask and grown 
overnight. Subsequently, cells were transiently transfected 
with the empty vector or the vector harboring SLC41A1 
and grown for a further 24 hours. Expression was verified 
by WB (Supplementary Figure 11).
T-REx™-HeLa cells stably expressing the Tet-
repressor were seeded at a density of two million cells 
per T-75 flask and grown for 24 hours prior transfection. 
Cells were then transiently transfected and allowed to 
recover for further 24 hours. Finally, protein expression 
was induced by the addition of tetracycline (1 μg/mL) 
for 24 hours. Control cells transfected with pcDNA5/
TO-SLC41A1 remained uninduced. Efficient expression 
of A1 in transiently transfected cells was controlled by 
immunoblotting with a primary mouse antibody directed 
against the Strep-tag (1:2,500, Qiagen) in combination 
with a horseradish peroxidase (HRP)-conjugated 
secondary antibody (anti-mouse, 1:2,000; from Cell 
Signaling Technology). No background expression in 
the absence of tetracycline was detected in HeLa cells as 
confirmed by immunoblotting (Supplementary Figure 11).
Cell preparation for label-free assays
HEK293(tet)↑(FLAG-SLC41A1) cells were 
harvested at 70-80% confluency and seeded into label-free 
fibronectin-coated microplates (PerkinElmer) in serum-
containing medium at a density of 20,000 cells/well. Post-
seeding, all cells were incubated at room temperature for 
30 minutes prior to overnight incubation under 5% CO2 at 
37°C. To induce protein expression, cells were incubated, 
as mentioned above, in label-free microplates.
Dynamic mass redistribution assay and imaging
Cells were washed three times in 25 μL/well assay 
buffer (Ca2+- and Mg2+-free Hank’s balanced saline (CMF-
HBSS, Biochrom) plus 10 mM HEPES pH 7.4 (CMF-
HBSS+)). Washing was carried out by using an aspiration 
wand and a multichannel pipette. The final volume was 
30 μL/well, and potential air bubbles were removed by 
centrifugation of the plate (400 rpm x 1 min). The label-
free microplates were equilibrated for 1 hour at 37°C in 
an EnSight Multimode Plate Reader (PerkinElmer). DMR 
signals were measured by using the EnSight Multimode 
Plate Reader equipped with Corning Epic® label-free 
technology (http://www.perkinelmer.com/pages/020/
labelfree/default.xhtml). An initial baseline measurement 
was taken for 30 min. The addition of SFLLR-NH2 
(5 μM), of Mg2+ (1, 3, or 10 mM), of Mg2+ (1, 3, or 10 
mM) and INS (400 μU/mL), or of assay buffer only was 
followed by a 36-min kinetic measurement. During the 
whole measurement, the EnSight Multimode Plate Reader 
was kept at a stable temperature of 37°C. The kinetic 
data were referenced to the last time point of the baseline 
measurement.
Brightfield images were acquired by using the well-
imaging module of the EnSight Multimode Plate Reader 
and were taken before the addition of the particular 
effector, but immediately after the label-free measurement 
and 90 min after the end of the measurement to allow for 
a cell confluence comparison over the duration of the 
experiment. Cell confluence was determined by using 
the pre-defined Brightfield Confluence analysis method 
with Kaleido Data Acquisition and Analysis Software 
(PerkinElmer) as provided by the plate reader.
PathScan® RTK signaling antibody 
array-(PRSA)-based investigation of the 
phosphorylation level of kinases and key 
signaling nodes in –tet and +tet cells
Four individual aliquots of –tet and +tet 
HEK293(tet)↑(FLAG-SLC41A1) cells were washed 
once with completely divalent-cation-free Dulbecco's 
phosphate-buffered saline (DPBS) and subsequently 
with CMF-HBSS+. After these washing steps, the first 
aliquots of –tet and +tet cells were directly lysed (C0) 
in 1x Cell Lysis Buffer (New England Biolabs), whereas 
the other aliquots were incubated in CMF-HBSS+ for 20 
min at 37°C (C1). Cells were subsequently pelleted and 
resuspended in CMF-HBSS+ plus 10 mM MgCl2 and 
incubated for 30 min at 37°C (C2). Finally, cells were 
transferred to CMF-HBSS+ supplemented with 400 μU/
mL INS and incubated for another 25 min (C3). After 
each change of the incubation conditions, one aliquot 
of –tet and +tet cells was lysed in 1x Cell Lysis Buffer. 
Unsolubilized material was pelleted by centrifugation 
(14,000 rpm, 10 min, 4°C). The protein concentration of 
the sample was determined with the Pierce 660 nm protein 
assay (Thermo Fisher Scientific), and lysates were diluted 
to a protein concentration of 0.8 mg/mL. The PRSA 
Kit (New England Biolabs) was used according to the 
manufacturer’s instructions. Cell lysates were incubated 
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on slides overnight at 4°C. The chemiluminescence 
detection of the spots was performed with the ChemiDoc 
MP imaging system (Bio-Rad), and spot intensities were 
quantified with the inbuilt software Image LabTM 5.2.1 
(Bio-Rad). The presented relative densities (RD) were 
calculated from the pixel densities of particular phospho-
signals normalized to the pixel densities of positive control 
spots printed on the chip.
Determination of phosphorylation status of Akt/
PKB in response to overexpression of A1
For the WB detection of Ser473- and Thr308-
phosphorylated Akt, –tet and +tet cells were treated 
exactly as described above for PRSA. Unsolubilized 
material was pelleted by centrifugation (14,000 rpm, 10 
min, 4°C), and the protein concentration was determined 
by the Pierce 660 nm protein assay (Thermo Fisher 
Scientific). For HEK293(tet)↑(FLAG-SLC41A1) cells, 
30 μg total protein was used for immunoblotting. The 
same protein amount was used for immunodetection 
with HeLa cells. For the detection of the phosphorylation 
status of Akt/PKB-Thr308 or Akt/PKB -Ser473 in SH-
SY5Y, 20 μg total protein were loaded for conditions C0-
C2 and 5 μg for C3. For the detection of Erk1/2-Thr202/
Tyr204 or total Erk1/2 in SH-SY5Y, 20 μg of total protein 
was used for all conditions. Protein samples were run 
on 10% SDS-PAA gels and transferred to polyvinylidene 
difluoride (PVDF) membranes. For immunodetection, 
(1) monoclonal rabbit antibodies recognizing either 
Akt/PKB-Thr308 or Akt/PKB -Ser473 (Phospo-Akt Thr308 
clone D25E6, and Phospo-Akt Ser473 clone D9E; both 
from New England Biolabs) diluted (1:800 and 1:1,000, 
respectively) in 2.5% milk TBS-T (Tris-buffered 
saline and Tween 20) were used in combination with a 
horseradish peroxidase (HRP)-conjugated secondary 
anti-rabbit antibody (1:2,500, Promega) or (2) polyclonal 
rabbit antibodies recognizing either Erk1/2-Thr202/
Tyr204 or total Erk1/2 (both from New England Biolabs) 
diluted (both 1:1,000) in 2.5% milk TBS-T were used 
in combination with a HRP-conjugated secondary anti-
rabbit antibody (1:2,500, Promega). An antibody against 
RPL19 (Abnova), together with an HRP-coupled anti-
mouse secondary antibody (Promega), was used to 
detect the loading control. Proteins were visualized with 
the Clarity™ ECL Western Blotting Substrate (Bio-
Rad). Image J software (http://rsb.info.nih.gov/ij/) and 
Image LabTM 5.2.1 software (BioRad) were used for the 
densitometric analysis of WB.
Relative adjusted densities (RAD) were calculated 
from the relative densities (RD) of Akt/PKB-Thr308 or 
Akt/PKB-Ser473 and of RPL19 bands (RAD = RDAkt/PKB /
RDRPL19).
RAD were calculated for Erk1/2 from RD of 
phosphorylated Erk1/2-Thr202/Tyr204 and of total Erk1/2 
bands (RAD = RDErk1/2-Thr202/Tyr204/RDErk1/2(total)).
RD were calculated as the pixel density (D) of the 
particular –tet and +tet bands obtained after treatment 
C0, C1, C2, or C3 divided by D of reference bands 
(corresponding to those obtained after treatment C0 in –
tet cells).
Due to inconsistencies in membrane stripping in 
SH-SY5Y and HeLa cells we decided for total protein 
staining as normalization method for the detection of 
Erk1/2-Thr202/Tyr204 phosphorylation in these cell lines. 
The TGX Stain-FreeTM FastCastTM Kit (Bio-Rad) was used 
to prepare 10% SDS-PAA gels. Protein detection with this 
technique is based on trihalo-compound modification of 
tryptophan residues and has proven to be superior to the 
conventional detection of housekeeping-proteins [68–70]. 
Loaded protein amounts were as described previously and 
gels for the detection of total and phosphorylated Erk1/2 
were run in parallel. Prior to immunoblotting the stain-
free gels were UV-activated for 1 min and pictures were 
taken using the ChemiDoc MP imaging system (Bio-
Rad, Supplementary Figure 12A, Supplementary Figure 
13A, Supplementary Figure 14A, Supplementary Figure 
15A). Proteins were transferred to PVDF membranes and 
proteins on the membrane were imaged and quantified 
using Image LabTM 5.2.1 software (Supplementary Figure 
12B, Supplementary Figure 13B, Supplementary Figure 
14B, Supplementary Figure 15B).
RD for total Erk1/2 and phosphorylated Erk1/2-
Thr202/Tyr204 was first normalized on total protein 
(RDErk1/2(total)/RDtotal protein = RDNErk1/2(total)) and RDErk1/2-Thr202/
Tyr204/RDtotal protein = RDNErk1/2-Thr202/Tyr204) and RAD were 
calculated from the normalized relative densities (RDN) of 
phosphorylated Erk1/2-Thr202/Tyr204 and normalized total 
Erk1/2 (RAD = RDNErk1/2-Thr202/Tyr204 /RDNErk1/2(total)).
Mag-fura 2 assisted Mg2+-measurements
The −tet and +tet HEK293(tet)↑(FLAG-SLC41A1) 
cells were rinsed twice with ice-cold, completely divalent, 
cation-free DPBS, detached by HyQtase (HyClone), 
centrifuged, washed in CMF-HBSS+, and resuspended in 
HBSS+ supplemented with [Mg2+] = 1 mM. Loading of 
cells with mag-fura 2 AM were performed as following: 
(C0) 30-min loading with mag-fura 2 in presence of 
[Mg2+]e = 1 mM. [Mg
2+]i were measured in –tet and +tet 
cells immediately after a 30-min loading period; (C1) 30-
min loading with mag-fura 2 in CMF-HBSS+. [Mg2+]i 
were measured in –tet and +tet cells immediately after a 
30-min loading period. Notably, the duration of the C1 
treatment for mag-fura 2-assisted [Mg2+]i measurements 
was extended by 10 min when compared with the duration 
of the C1 treatment in phosphorylation experiments. 
This extension was necessary to allow for the sufficient 
mag-fura 2 AM loading into cells and its activation 
(de-esterification) by intracellular esterases; (C2) 30-
min loading with mag-fura 2 in CMF-HBSS+ plus 30-
min incubation of the cells in HBSS+ containing 10 
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mM Mg2+. [Mg2+]i were measured in –tet and +tet cells 
immediately after 30-min Mg2+ loading period; (C3) 30-
min loading with mag-fura 2 in Mg2+-free HBSS+ plus 
30 min incubation of the cells in HBSS+ containing 10 
mM Mg2+ and followed by 25-min incubation of the 
cells in CMF-HBSS+ provided with INS (400 μU/mL, 
measuring solution). The following [Mg2+]e were present 
in the measuring media under the respective conditions: 
C0, 1 mM; C1, 0.00 mM; C2, 10 mM; C3, 0.00 mM. 
Moreover, under C3, INS (400 μU/mL) was added to the 
measuring medium. Measurements were executed at 37°C 
in 3-ml cuvettes containing 2 ml cell suspension while 
being stirred. [Mg2+]i were determined by measuring the 
fluorescence of the probe-loaded cells in a spectrometer 
(LS50B and LS55, both PerkinElmer Life Science) by 
using the fast-filter accessory (340/380 nm; PerkinElmer 
Life Science). [Mg2+]i values were calculated according to 
previous reports 10,13,20. Minimum (Rmin) and maximum 
(Rmax) ratios for calibration were determined at the end 
of each experiment by using digitonin (SigmaAldrich). 
Rmax was found by the addition of MgCl2 to its final 
concentration of 25 mM in the absence of Ca2+, whereas 
Rmin was obtained by the addition of 50 mM EDTA, pH 
7.2 (SigmaAldrich). Averaged values of [Mg2+]i were 
calculated from 20-s data sets. The effective frequency of 
data acquisition was 20 ms. Thus, for the calculation of 
any given averaged [Mg2+]i, 1000 data points were used. 
Measurements for each respective group were acquired at 
least on three separate occasions.
Statistics
(1) The two-tailed Student’s t-test was used to 
compare differences between two means (Tables 1, 2, 
Figures 5, 8, 10, Supplementary Figure 3, Supplementary 
Figure 5, Supplementary Figure 7, Supplementary Figure 
9). (2) A post hoc Tukey one-way analysis of variance 
(ANOVA) or Kruskal–Wallis one-way ANOVA on ranks 
was used to perform a multiple comparison between 
treatment groups (C0, C1, C2, and C3) in the –tet or +tet 
groups (Table 3, Figures 6, 8, 10, Supplementary Figures 
3, 5, 9). A Shapiro-Wilk normality test was used for (2). 
Data are presented as means ± SE. Differences of P < 
0.05 were considered significant. Statistical analyses were 
executed by means of SigmaPlot 11.0 (Systat Software, 
Inc.). The same software was used to generate graphs.
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